Alpha Tau Medical (NASDAQ:DRTS) Issues Earnings Results, Misses Estimates By $0.01 EPS

Alpha Tau Medical (NASDAQ:DRTS) announced its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01), Zacks reports.

Alpha Tau Medical Trading Down 2.0%

Alpha Tau Medical stock opened at $6.58 on Tuesday. The firm has a market capitalization of $557.69 million, a P/E ratio of -12.67 and a beta of 1.02. The stock has a fifty day moving average price of $6.94 and a 200 day moving average price of $5.07. Alpha Tau Medical has a 52 week low of $2.30 and a 52 week high of $8.60.

Hedge Funds Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of DRTS. Envestnet Asset Management Inc. acquired a new stake in shares of Alpha Tau Medical in the third quarter worth $62,000. Bank of America Corp DE lifted its holdings in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after buying an additional 21,677 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical in the 3rd quarter valued at approximately $170,000. Finally, Mariner LLC boosted its stake in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares during the last quarter. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Citigroup reduced their price target on Alpha Tau Medical from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, December 10th. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. HC Wainwright restated a “buy” rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Piper Sandler reiterated a “neutral” rating and set a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.